Polygala tenuifolia: a source for anti-Alzheimer's disease drugs

Pharm Biol. 2020 Dec;58(1):410-416. doi: 10.1080/13880209.2020.1758732.

Abstract

Context: Alzheimer's disease (AD) is a chronic neurodegenerative disease that originates from central nervous system lesions or recessions. Current estimates suggest that this disease affects over 35 million people worldwide. However, lacking effective drugs is the biggest handicap in treating AD. In traditional Chinese medicine (TCM), Polygala tenuifolia Willd. (Polygalaceae) is generally used to treat insomnia, memory dysfunction and neurasthenia.Objective: This review article explores the role of P. tenuifolia and its active components in anti-Alzheimer's disease.Methods: Literature for the last ten years was obtained through a search on PubMed, SciFinder, CNKI, Google Scholar, Web of Science, Science Direct and China Knowledge Resource Integrated with the following keywords: Polygala tenuifolia, polygalasaponin XXXII (PGS 32), tenuifolin, polygalacic acid, senegenin, tenuigenin, Alzheimer's disease.Results: Polygala tenuifolia and its active components have multiplex neuroprotective potential associated with AD, such as anti-Aβ aggregation, anti-Tau protein, anti-inflammation, antioxidant, anti-neuronal apoptosis, enhancing central cholinergic system and promote neuronal proliferation.Conclusions: Polygala tenuifolia and its active components exhibit multiple neuroprotective effects. Hence, P. tenuifolia is a potential drug against Alzheimer's disease, especially in terms of prevention.

Keywords: Polygalasaponin XXXII; multitarge; neuroprotective effects; polygalacic acid; senegenin; tenuifolin; tenuigenin.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / metabolism
  • Alzheimer Disease* / pathology
  • Amyloid beta-Peptides / antagonists & inhibitors
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Humans
  • Neurodegenerative Diseases / drug therapy
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / pathology
  • Neurons / drug effects
  • Neurons / metabolism
  • Neurons / pathology
  • Neuroprotective Agents* / isolation & purification
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • Plant Extracts* / isolation & purification
  • Plant Extracts* / pharmacology
  • Plant Extracts* / therapeutic use
  • Polygala*

Substances

  • Amyloid beta-Peptides
  • Neuroprotective Agents
  • Plant Extracts
  • tenuifolic saponin

Grants and funding

This study was supported by the National Natural Science Foundation of China [grant number. 81860755, 21606137], the Key Research and Development Programme of Ningxia [grant number: 2018BFH02001 and 2018BFH03023], Ningxia University’s First-Class Subject (Traditional Chinese Medicine) Construction Project [grant number: NXYLXK2017A06].